This study compared the number of, and expenditures on, first-line intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections between patients who were treated with aflibercept or ranibizumab for wet age-related macular degeneration (AMD). ranibizumab patients (in multivariable regression treating ranibizumab as reference: incidence rate ratio = 0.97, 95% confidence interval [CI] 0.91-1.03, P = 0.277; cost ratio = 0.96, 95% CI 0.89-1.04, P = 0.338).
INTRODUCTION
Age-related macular degeneration (AMD) is an eye condition that causes destruction of the macula, leading to losses of vision that can be severe enough as to constitute legal blindness [1] . Prior to the advent of anti-vascular endothelial growth factor (anti-VEGF) therapy, AMD was the most common cause of vision loss among individuals in the United States, with a prevalence of 6.5% among people aged 40 years and older [1, 2] . AMD can be either nonexudative (atrophic or dry) or exudative (neovascular or wet). Dry AMD accounts for 90% of U.S. AMD cases, is associated with sequelae that in most cases are comparatively less severe than those seen in wet AMD, and is generally managed through observation with no medical or surgical therapies and/or antioxidant vitamin and mineral supplements [3, 4] . In contrast, wet AMD causes the great majority of severe vision loss and legal blindness, and is managed through a variety of treatment modalities including photodynamic therapy, laser surgery, and intravitreal injections of anti-VEGF agents [4, 5] . Anti-VEGF therapy has now become the standard of care for treating wet AMD disease.
Currently, there are three intravitreal anti-VEGF treatments approved by U.S. Food and Drug Administration (FDA) for the treatment of wet AMD: pegaptanib (approved 2004), ranibizumab (approved 2006), and aflibercept (approved 2011) [6] [7] [8] . Bevacizumab is not approved by the FDA for the treatment of wet AMD, but is nevertheless used for this purpose off-label. Among the three FDA-approved intravitreal anti-VEGF treatments, ranibizumab and aflibercept are the most commonly used agents, while pegaptanib is rarely used.
Based on findings from the HARBOR study (The pHase III, double-masked, multicenter, randomized, Active treatment-controlled study of the efficacy and safety of 0.5 and 2.0 mg Ranibizumab administered monthly or on an as-needed Basis (PRN) in patients with subfoveal neovascular AMD study), the package insert for ranibizumab was recently expanded to include less-than-monthly dosage and administration options after 3 initial monthly doses in addition to the originally recommended once-monthly frequency [9] . Although the ranibizumab 0.5 mg PRN regimen did not meet the noninferiority endpoint compared to the ranibizumab 0.5 mg monthly regimen at 12 months in the HARBOR study, it still led to rapid, sustained and clinically meaningful vision gains out to 24 months (9.1 letters for the monthly regimen and 7.9 letters for the PRN regimen). The package insert recommended dosage and administration for aflibercept is once monthly for the first three months followed by once every other month, although dosing as frequently as monthly is an alternative regimen.
The potential for less frequent injections of aflibercept and ranibizumab, which could translate to fewer physician visits and lower cost of anti-VEGF treatment, is appealing to patients and payers alike. However, the use of treatments in 'real world' clinical practice may be different from what is stipulated in the package inserts. Thus, the aim of this study is to examine first-line intravitreal anti-VEGF treatment patterns in wet AMD patients, specifically comparing the number of, and expenditures on, intravitreal anti-VEGF injections between patients who are treated with aflibercept or ranibizumab.
MATERIALS AND METHODS

Data Source
This study's data source was U.S. health insurance claims data extracted from the In an attempt to generate results that were reflective of the variety of ways in which intravitreal anti-VEGF therapies may be prescribed, all patients meeting the criteria above were included for study, irrespective of the potential treatment strategy that a physician may have been using for a given patient (e.g., monthly, PRN, or treat and extend).
Follow-up Period and Outcomes
For each patient, a follow-up period was established that extended from their index date until the first occurrence of one of the following events: switch to a different anti-VEGF agent, disenrollment from health insurance, inpatient death, or reaching April 30, 2013. This study focused on two patient samples, those with follow-up periods that lasted 6 months or longer and those with follow-up periods that lasted 12 months or longer.
The primary outcomes were measured within the first 6 months and first 12 months of the follow-up period and included the number of intravitreal anti-VEGF injections and healthcare expenditures on intravitreal anti-VEGF injections. The days elapsed between each intravitreal anti-VEGF injection were also calculated. Healthcare expenditures were measured using the financial fields on administrative claims in the MarketScan Databases and included the gross covered payments for the anti-VEGF agent alone (i.e., not including the payments associated with intravitreal administration procedure), which includes deductibles, copayments, coordination of benefits and the amount eligible for payment after applying pricing guidelines such as fee schedules and discounts.
A secondary outcome-days between intravitreal anti-VEGF injections-was examined in a supplementary analysis. For this analysis, all patients who met the study inclusion criteria, except those related to minimum durations of follow-up were included in an effort to increase sample sizes. That is, all patients with 2 or more injections were used to calculate the mean days between the first and second injections, all patients with 3 or more injections were used to calculate the mean days between the second and third injections, and so on, regardless of having 6 months or 12 months of follow-up.
Covariates
Several covariates, including demographics and clinical characteristics that are potentially relevant to AMD and the use of intravitreal anti-VEGF therapies, were measured throughout the baseline period to describe the study sample and to be used in the [11] . The codes and specific criteria used to measure the covariates are described in Appendix B.
Statistical Analyses
Bivariate descriptive summary statistics were used to display the study outcomes, stratified and 12 months after the index date. In the 6 month analyses, the mean number of injections was 3.8 in the aflibercept patients and 3.9 in the ranibizumab patients. Multivariable regression adjusting for patient demographics and clinical characteristics determined that the number of injections did not differ in a statistically significant manner between aflibercept patients and ranibizumab patients ( Organization (vs. fee-for-service) (IRR = 0.80, 95% CI 0.72-0.90, P\0.001) and having baseline treatment with intravitreal steroid injection (IRR = 0.92, 95% CI 0.85-0.98, P = 0.015). Factors that were significantly associated with receiving more intravitreal anti-VEGF injections included being aged 75-84 (vs. 85?) years (IRR = 1.07, 95% CI 1.00-1.13, P = 0.035) and having baseline treatment with non-intravitreal glucocorticoids (IRR = 1.14, 95% CI 1.05-1.24, P = 0.002). In the 12 month analyses, the mean number of injections was 5.5 in the aflibercept patients and 5.8 in the ranibizumab patients. Again, the number of injections did not differ in a statistically significant manner between aflibercept patients and ranibizumab patients ( Multivariable regression determined that the In the 12 month analyses, the mean expenditure on injections was $11,052 in the aflibercept patients and $11,342 in the ranibizumab patients. Again, expenditures on injections did not differ in a statistically significant manner between aflibercept patients and ranibizumab patients ( Table 4: CR   treating ranibizumab as reference category = 0.92, 95% CI 0.74-1.13, P = 0.4291).
In sensitivity analyses including patients in the 12 month analyses who had initiated ranibizumab prior to the aflibercept approval date of November 18, 2011 (N = 8,519), study findings were generally similar to the primary analyses-with the mean number of injections 
DISCUSSION
This retrospective analysis examined first-line intravitreal anti-VEGF treatment patterns in wet AMD. Comparing between patients who were treated with aflibercept or ranibizumab, the two newest and most commonly used FDAapproved therapies for wet AMD, we found that the number of intravitreal anti-VEGF injections and healthcare expenditures on intravitreal anti-VEGF injections did not differ in a statistically significant manner. To our knowledge, this is the first study to examine these outcomes in the 'real world' setting of routine clinical practice. Thus, our findings are a new and unique contribution to the literature. 
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